Latest Stock Exchanges News

Assetora Limited is set to be delisted from the ASX after a two-year suspension, with the company exploring a fresh listing on the National Stock Exchange of Australia to better suit its evolving business model.

PLS Group has locked in a two-year offtake agreement with Canmax Technologies for 150,000 tonnes per annum of spodumene concentrate, backed by a $100 million interest-free prepayment and a price floor to protect against market dips.

Ariana Resources has extinguished its outstanding US$782,575 loan with RiverFort by issuing over 40 million shares, leaving the company debt-free and well-capitalised with A$11 million in cash.

Toro Energy shareholders are set to gain exposure to a diversified uranium portfolio through IsoEnergy’s acquisition offer at a near 80% premium, while Toro advances its Wiluna Uranium Project amid strong market tailwinds.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

GCM Corporation’s latest quarterly report confirms its VHD thermal management technology outperforms copper and aluminium, while commercial and US listing plans gain momentum.

Pacific Lime and Cement Limited reports steady progress on its Central Lime Project in Papua New Guinea, securing key government agreements and strategic partnerships while maintaining financial discipline.

Yugo Metals has made promising progress with diamond drilling at its Sinjakovo project, intersecting silver-zinc-lead mineralisation, while securing $3.5 million in new funding and expanding its investor reach through a dual listing in Germany.

Findi Limited has responded in detail to ASX queries over its valuation approach for its Indian subsidiary TSI, clarifying peer selection, valuation multiples, and compliance ahead of TSI’s planned IPO on the Bombay Stock Exchange.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.